Page last updated: 2024-10-25

ciglitazone and Pneumonia

ciglitazone has been researched along with Pneumonia in 2 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Pneumonia: Infection of the lung often accompanied by inflammation.

Research Excerpts

ExcerptRelevanceReference
"Ciglitazone ameliorates the inflammatory response and may reduce lung injury after hemorrhagic shock."7.74Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. ( Chima, RS; Denenberg, A; Hake, PW; Mangeshkar, P; Piraino, G; Zingarelli, B, 2008)
"Ciglitazone ameliorates the inflammatory response and may reduce lung injury after hemorrhagic shock."3.74Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. ( Chima, RS; Denenberg, A; Hake, PW; Mangeshkar, P; Piraino, G; Zingarelli, B, 2008)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chima, RS1
Hake, PW1
Piraino, G1
Mangeshkar, P1
Denenberg, A1
Zingarelli, B1
Ward, JE1
Fernandes, DJ1
Taylor, CC1
Bonacci, JV1
Quan, L1
Stewart, AG1

Other Studies

2 other studies available for ciglitazone and Pneumonia

ArticleYear
Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock.
    Critical care medicine, 2008, Volume: 36, Issue:10

    Topics: Animals; Blood Glucose; Chemokines; Cytokines; Disease Models, Animal; Immunohistochemistry; Inflamm

2008
The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation.
    Pulmonary pharmacology & therapeutics, 2006, Volume: 19, Issue:1

    Topics: Allergens; Animals; Bronchoalveolar Lavage Fluid; Bronchoconstrictor Agents; Disease Models, Animal;

2006